Chromosomal instability and the resulting aneuploidy are detrimental to non-cancer cells. However, more than 80% of all cancers are aneuploid, suggesting that cancer cells have found ways to cope with the consequences of CIN. Therefore, interfering with these coping mechanisms could be a powerful way to treat aneuploid cancers. While finding such CIN-related intervention strategies is very much ongoing in the lab, we recently discovered that cells with a CIN phenotype are much more sensitive to inhibition of a kinase, Src kinase, compared to cells that do not display CIN. We find that Src inhibition acts synergistically with established anti-cancer drugs that provoke CIN. Therefore, our findings could be a first step towards combination therapy of Src inhibition with established anti-cancer drugs.